Ram Challapalli, MD
Cardiovascular Disease · Reno, NVNPI 1154313815
Payments from drug & device makers
Across 650 payments — averaging $26.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biosense Webster, Inc.$4K
- Biotronik Inc.$4K
- Boston Scientific$3K
- Abbott$1K
- Novartis$928
- Medical Device Business Services, Inc.$745
- plus $4K from 32 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biosense Webster, Inc. | 241 | $4,402 |
| Biotronik Inc. | 83 | $3,709 |
| Boston Scientific | 89 | $2,848 |
| Abbott | 17 | $1,331 |
| Novartis | 54 | $928 |
| Medical Device Business Services, Inc. | 3 | $745 |
| Medtronic(2 entities) | 42 | $735 |
| Atricure, Inc. | 13 | $558 |
| Johnson & Johnson | 22 | $277 |
| Bayer | 9 | $229 |
| Amgen | 11 | $204 |
| Pfizer | 8 | $169 |
| Lexicon Pharmaceuticals, Inc. | 6 | $141 |
| Edwards Lifesciences | 5 | $139 |
| Amarin Pharma, Inc. | 1 | $129 |
| Actelion Pharmaceuticals US, Inc. | 6 | $105 |
| E.r. Squibb & Sons, L.L.C. | 4 | $89 |
| Boehringer Ingelheim | 4 | $78 |
| Cvrx, Inc. | 3 | $71 |
| Esperion Therapeutics, Inc. | 4 | $68 |
| Philips North America LLC | 2 | $51 |
| AstraZeneca(2 entities) | 3 | $48 |
| Kowa Pharmaceuticals America, Inc. | 2 | $46 |
| Heartflow, Inc. | 2 | $46 |
| Cordis US CORP. | 1 | $45 |
| Regeneron Healthcare Solutions, Inc. | 2 | $45 |
| Abiomed | 2 | $38 |
| Siemens Medical Solutions USA, Inc. | 1 | $32 |
| Scpharmaceuticals Inc. | 1 | $31 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $27 |
| Convatec Inc. | 1 | $22 |
| Elutia, Inc. | 1 | $21 |
| Baxter Healthcare | 1 | $21 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $20 |
| Teleflex LLC | 1 | $19 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $18 |
| Alnylam Pharmaceuticals Inc. | 1 | $15 |
| Impulse Dynamics (USA) Inc. | 1 | $14 |
How this compares
$17,513 in reported general payments places this provider in the 80th percentile of 165 cardiovascular disease providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other cardiovascular disease in Reno
- Thomas-Duythuc ToReno$1.1M
- Joseph StevensonReno$363K
- Christopher RowanReno$280K
- Jay MasonReno$227K
- Devang DesaiReno$206K
- Anita KediaReno$9K
- Sridevi ChallapalliReno$8K
- Christopher WilsonReno$7K
- Ramprasad DandillayaLas Vegas$1.8M
- Chowdhury AhsanLas Vegas$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.